{"analyses":[{"ciLowerLimit":"1.22","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.63","groupDescription":"\\< 1% PD-L1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Treatment A vs Treatment B","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.79"},{"ciLowerLimit":"0.61","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.96","groupDescription":"≥1% PD-L1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Treatment A vs Treatment B","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.77"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.7","upperLimit":"5.6","value":"4.1"},{"groupId":"OG001","lowerLimit":"7.0","upperLimit":"11.1","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"title":"<1% PD-L1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.8","upperLimit":"8.5","value":"7.0"},{"groupId":"OG001","lowerLimit":"6.2","upperLimit":"7.6","value":"7.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"219"}],"units":"Participants"}],"title":"≥1% PD-L1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"297"}],"units":"Participants"}],"description":"PD-L1 Expression is defined as the percent of tumor cells membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 immunohistochemistry (IHC) assay. This is referred to as quantifiable PD-L1 expression and efficacy is determined by progression free survival (PFS) analysis. PFS is defined as the time between the date of randomization and the date of first documented tumor progression per Blinded Independent Central Review (BICR) assessments (using adapted m-RECIST and RECIST 1.1), or death due to any cause, whichever occurs first. Participants who received subsequent anticancer therapy prior to documented progression were censored at the date of the last evaluable tumor assessment conducted on or prior to the date of initiation of the subsequent anticancer therapy.\n\nProgressive disease (PD)=At least a 20% increase in the sum of the Total Tumor Measurement.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg IV Q2W + Ipilimumab 1 mg/kg IV Q6W","id":"OG000","title":"Treatment A"},{"description":"Pemetrexed 500 mg/m\\^2 + Cisplatin 75 mg/m\\^2 or Carboplatin 5 AUC up to 6 cycles","id":"OG001","title":"Treatment B"}],"paramType":"MEDIAN","populationDescription":"All PD-L1 evaluable participants with baseline expression \\<1% or ≥1%","reportingStatus":"POSTED","timeFrame":"From randomization date to the date of first documented tumor progression or death due to any cause, whichever occurs first. (up to 76 months)","title":"Progression Free Survival (PFS) According to PD-L1 Expression Level","type":"SECONDARY","unitOfMeasure":"Months"}